m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00443)
Name
MSX-122
Status
Phase 1
Structure
Formula
C16H16N6
InChI
1S/C16H16N6/c1-7-17-15(18-8-1)21-11-13-3-5-14(6-4-13)12-22-16-19-9-2-10-20-16/h1-10H,11-12H2,(H,17,18,21)(H,19,20,22)
InChIKey
PXZXYRKDDXKDTK-UHFFFAOYSA-N
PubChem CID
11687907
TTD Drug ID
D0E5JC
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
C-X-C chemokine receptor type 4 (CXCR4)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for MSX-122. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of MSX-122 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). [1], [2]
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for MSX-122. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of MSX-122 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). [2], [3]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary C-X-C chemokine receptor type 4 (CXCR4) is a therapeutic target for MSX-122. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of MSX-122 through regulating the expression of C-X-C chemokine receptor type 4 (CXCR4). [1], [2]
References
Ref 1 m(6)A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019 Jun 25;10(1):2782. doi: 10.1038/s41467-019-10669-0.
Ref 2 Therapeutic antibodies directed at G protein-coupled receptors. MAbs. 2010 Nov-Dec; 2(6): 594-606.
Ref 3 LNC942 promoting METTL14-mediated m(6)A methylation in breast cancer cell proliferation and progression. Oncogene. 2020 Jul;39(31):5358-5372. doi: 10.1038/s41388-020-1338-9. Epub 2020 Jun 23.